Screening for inducers of apoptosis in apoptosis-resistant human carcinoma cells

K Umezawa1, K Nakazawa, Y Uchihata

  • 1Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Japan.

Insights

Researchers screened for compounds that induce apoptosis in resistant pancreatic cancer cells. Polyoxypeptin A and HPH-3 were identified as potent apoptosis inducers, offering new avenues for anticancer drug development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Human solid tumor cells, including pancreatic adenocarcinoma AsPC-1 cells, often exhibit resistance to apoptosis induction by anticancer agents.
  • Identifying novel compounds that can overcome this resistance is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To screen microbial culture filtrates and synthetic chemicals for their ability to induce apoptosis in resistant AsPC-1 cells.
  • To identify and characterize novel apoptosis-inducing agents.

Main Methods:

  • Screening of microbial culture filtrates and synthetic chemicals.
  • Isolation and structural elucidation of active compounds (Polyoxypeptin A, BE-14106, HPH-3).
  • Assessment of apoptosis induction via cell death, morphology, and DNA fragmentation assays.
  • Investigation of caspase activation and ion-dependent mechanisms.

Main Results:

  • Polyoxypeptin A, a cyclic hexadepsipeptide containing a novel amino acid, potently induced apoptosis in AsPC-1 cells.
  • BE-14106, a macrocyclic lactam, also demonstrated apoptosis-inducing activity in AsPC-1 cells.
  • HPH-3, a bleomycin-derived ligand, induced apoptosis in AsPC-1 cells, dependent on chelation with ferrous ions, unlike Bleomycin A2 or GP-3.

Conclusions:

  • Polyoxypeptin A and HPH-3 are novel, potent inducers of apoptosis in resistant human pancreatic adenocarcinoma cells.
  • HPH-3's apoptosis-inducing mechanism involves metal ion chelation, distinct from DNA cleavage.
  • Further development of less toxic polyoxypeptin A derivatives and understanding HPH-3's precise mechanism are warranted for potential anticancer applications.